These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting]. Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282 [No Abstract] [Full Text] [Related]
3. The parenteral drug industry: recent findings. Fry EM J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464 [No Abstract] [Full Text] [Related]
4. FDA bans firms from importing and distributing contaminated animal drugs. J Am Vet Med Assoc; 1999 May; 214(10):1459. PubMed ID: 10340065 [No Abstract] [Full Text] [Related]
6. Regulators scramble to tighten loopholes after heparin debacle. Jia H Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756 [No Abstract] [Full Text] [Related]
7. Biotech jostles with pharma for slice of HIV market. Katsnelson A Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375 [No Abstract] [Full Text] [Related]
8. FDA takes action against firms in scandal over generic products. Pollner F Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736 [No Abstract] [Full Text] [Related]
9. Counterfeiting and piracy of pharmaceuticals. Grackin A IEEE Eng Med Biol Mag; 2008; 27(6):66-9. PubMed ID: 19004698 [No Abstract] [Full Text] [Related]
11. Current good manufacturing practice: proposed revision of certain requirements for finished pharmaceuticals; proposed rule, May 3, 1996 (61 FR 20103), [Docket No. 95N-0362]. Parenteral Drug Association. PDA J Pharm Sci Technol; 1996; 50(6):346-51. PubMed ID: 9038078 [No Abstract] [Full Text] [Related]
12. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
14. Quality control and good manufacturing practices: safety and efficacy of commercial herbals. Awang DV Food Drug Law J; 1997; 52(3):341-4. PubMed ID: 10343036 [No Abstract] [Full Text] [Related]
15. Frustrated by regulatory delays at FDA, biotech companies warm to user fees. Gershon D Nature; 1992 Aug; 358(6388):616. PubMed ID: 1495553 [No Abstract] [Full Text] [Related]
16. Regulatory evaluation of biotechnology drugs: current trends in the United States. Sobel S Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148 [No Abstract] [Full Text] [Related]
17. Biotech drugs come of age; policymakers take notice. Iglehart JK Health Aff (Millwood); 2006; 25(5):1202-3. PubMed ID: 16966714 [No Abstract] [Full Text] [Related]
19. Responsible extra-label use of drugs. Cobb DV J Am Vet Med Assoc; 1996 Nov; 209(9):1545. PubMed ID: 8899012 [No Abstract] [Full Text] [Related]
20. Beyond the lab in biotech. With so many drugs in trial, new jobs are opening up. Carmichael M Newsweek; 2002 Sep; 140(13):53. PubMed ID: 12375414 [No Abstract] [Full Text] [Related] [Next] [New Search]